Home › Multiple Myeloma › NCT07341867

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

A Pilot Study of Duffy Null-Specific Dose Modifications for Individuals With Duffy Null Phenotype Receiving Standard of Care Systemic Anti-Cancer Therapies

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Diagnosis of:

  * Cohort 1: MM, based on IMWG criteria12, and currently requires treatment
  * Cohort 2: Stage II or III TNBC, with definition per protocol Section 3.2.1 AND
* Plan for treatment, per their treating physician, or currently receiving their first cycle (see 3.3.3 for definition) of:

  * Cohort 1: Dara-RVd for MM
  * Cohort 2: A Keynote 522-based regimen of carboplatin, paclitaxel, and pembrolizumab given as the first phase of neoadjuvant treatment for TNBC.\*\*\*

    * Participants are eligible even if the duration of carboplatin and paclitaxel goes beyond 4 cycles, or if the use of pembrolizumab, doxorubicin, and cyclophosphamide is not planned or is not certain, as long as neoadjuvant treatment starts with carboplatin-paclitaxel-pembrolizumab. This cohort will be referred to as "Keynote 522" for the remainder of the protocol.

AND

* Confirmed Duffy null phenotype

  * Previous testing is acceptable if performed by a CLIA-approved test

AND

* Age \>=18 years old

Exclusion Criteria:

* Inability to understand and the willingness to sign a written informed consent document
* ANC\<500 within 7 days of planned start of Cycle 1 Day 1.
* Participants who have started treatment at the time of enrollment cannot have started Cycle 2 of therapy
* Participants in Cohort 2 (TNBC) cannot have received any of the pembrolizumab, doxorubicin, and cyclophosphamide portion of therapy
* Participants receiving any other investigational agents for any indication
* Another known condition or medicine with known impacts on neutrophil counts or neutrophil function

About the study

This study is comprised of a main study, an observational study, and optional survey studies. The main study is being done to see whether using Duffy null specific treatment dosing guidelines can reduce or delay dose modifications and avoid neutropenic fever (fever in the setting of low neutrophils) for people with Duffy null phenotype receiving treatment for multiple myeloma or triple negative breast cancer. The observational study is to collect dose modification and neutropenic fever information on patients who do not have the Duffy null phenotype and receive the same standard of care regimens to see if there are differences in dose modifications and neutropenic fever between the two groups. The survey studies seek to understand general health experiences and preferences and experiences specific to people with Duffy null phenotype.

Study Drugs Include:

* Daratumumab * lenalidomide * bortezomib * dexamethasone * carboplatin * paclitaxel * pembrolizumab * cyclophosphamide * doxorubicin

What is being tested

• Dexamethasone (drug)
• Bortezomib (drug)
• LENALIDOMIDE (drug)
• Daratumumab (drug)
• Carboplatin (drug)
• Paclitaxel (drug)

Sponsor: Andrew Hantel, MD · Participants: 90 · Started: Jul 30, 2026

Contact the study team

• Andrew Hantel, MD · Phone: 617-582-9394

Official record on ClinicalTrials.gov — NCT07341867

Locations in the U.S.

Conditions

• Multiple Myeloma
• Triple-Negative Breast Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.